Related Experiment Video
Updated: May 28, 2025

A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells
Published on: May 6, 2018
Dual functional nanoplatforms potentiate osteosarcoma immunotherapy via microenvironment modulation
Shunyi Lu1,2, Yuqi Yang2, Zhuorun Song1,2
1Department of Orthopedic Surgery, The First Affiliated Hospital of Soochow University, Suzhou 215123, China.
Abstract:
Osteosarcoma (OS), a highly aggressive bone tumor, presents significant challenges in terms of effective treatment. We identified that cellular autophagy was impaired within OS by comparing clinical OS samples through bioinformatic analyses and further validated the inhibition of mitochondrial autophagy in OS at the transcriptomic level. Based on this finding, we investigated the therapeutic potential of a dual functional metal nanoplatform (MnSx) to facilitate a transition from the protective effect of low-level autophagy in OS to the killing effect of high-level autophagy in OS. MnSx facilitated intracellular H2S generation via endocytosis, leading to the S-sulfhydration of ubiquitin-specific peptidase 8 (USP8) and subsequent promotion of mitochondrial autophagy in vitro. Additionally, MnSx activated the cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS)-stimulator of interferon genes (STING) pathway, further enhancing the cellular autophagic response and accelerating tumor cell death. Moreover, it was demonstrated in vivo that MnSx, on the one hand, mediated the activation of tumor autophagy by USP8 via intracellular H2S, while Mn2+ promoted the maturation of dendritic cells, activated cytotoxic T lymphocytes and contributed to tumor eradication. Such tumor killing could be suppressed by the autophagy inhibitor chloroquine. Importantly, synergistic combination therapy with immune checkpoint inhibitors showed promise for achieving complete remission of OS. This study highlights the potential of MnSx as a dual-functional therapeutic platform for OS treatment and offers novel directions for future research in this field.
Insights
This study reveals that impaired autophagy in osteosarcoma (OS) can be therapeutically targeted. A novel manganese sulfide nanoplatform (MnSx) reactivates autophagy and enhances anti-tumor immunity for effective osteosarcoma treatment.
Area of Science:
- Biomedical Engineering
- Oncology
- Immunology
Background:
- Osteosarcoma (OS) is an aggressive bone tumor with limited treatment options.
- Cellular autophagy is impaired in OS, hindering effective therapeutic strategies.
- Mitochondrial autophagy inhibition is a key feature observed at the transcriptomic level in OS.
Purpose of the Study:
- To investigate the therapeutic potential of a dual-functional metal nanoplatform (MnSx) for osteosarcoma (OS).
- To explore MnSx's ability to shift autophagy from a protective role to a tumor-killing effect in OS.
- To evaluate MnSx's efficacy in combination with immune checkpoint inhibitors for complete OS remission.
Main Methods:
- Bioinformatic analysis of clinical OS samples to identify impaired autophagy.
- Transcriptomic analysis to validate mitochondrial autophagy inhibition in OS.
- In vitro and in vivo studies using MnSx nanoplatform for therapeutic intervention.
Main Results:
- MnSx facilitates intracellular H2S generation, promoting mitochondrial autophagy via USP8 S-sulfhydration.
- MnSx activates the cGAS-STING pathway, enhancing autophagy and tumor cell death.
- In vivo, MnSx activates autophagy, matures dendritic cells, and activates cytotoxic T lymphocytes, leading to tumor eradication.
Conclusions:
- MnSx shows potential as a dual-functional therapeutic platform for osteosarcoma.
- Targeting autophagy via MnSx offers a novel strategy for OS treatment.
- Combination therapy with immune checkpoint inhibitors holds promise for complete OS remission.
Related Concept Videos
Tumor Immunotherapy
The Tumor Microenvironment

